Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
Detection of Glioblastoma or Anaplastic Astrocytoma Cells in the Circulation During Surgical Resection
2 other identifiers
observational
25
1 country
1
Brief Summary
Glioblastomas, the most frequent malignant brain tumor in adults, are widespread in the brain, despite their discrete appearance on computed tomography (CT) or magnetic resonance imaging (MRI). While this tumor tends to spread widely in the brain, unlike other tumors of the body, it rarely metastasizes, or spreads, to other organs. Approximately 10 percent of patients with glioblastoma develop metastatic disease after radiation or brain surgery. In the absence of radiation or brain surgery, few patients have developed disease spread outside the brain. During surgery to remove tumors of other organs of the body, such as the lung, prostate, kidney, or ovary, cells from these tumors are routinely found in the bloodstream. These cells are believed to be the reason for the spread of these tumors. In the case of malignant brain tumors, this process of glioma (tumor) cells shedding into circulation has not yet been investigated. This study will determine whether glioma cells can be detected in the bloodstream of patients undergoing surgery. If glioma cells are absent, it may mean they are unable to penetrate the blood-brain barrier. If they are present, they presumably can penetrate into blood vessels but they may be recognized and eliminated by the immune system, or they may escape detection yet not be able to take hold in the new microenvironment. The results of the study will add to the knowledge of the biology of these highly malignant tumors. Study participants will be admitted to the hospital for 8 to 10 days. They will undergo a complete physical and neurological exam and blood and urine tests. An electrocardiogram will be performed, and x-rays may be taken. On the morning of surgery, the patient will receive sedation intravenously. A tiny plastic tube called a catheter will be introduced into a vein in the groin through needles. The catheter will be passed through to the jugular bulb, right above the jugular vein, on the same side as the tumor. The patient will then be taken to the operating room for surgery. During surgery, not more than one quarter of a unit of blood will be removed through the catheter. The catheter will be removed before the patient enters the intensive care unit. Another MRI will be taken after surgery. The study will enroll participants for 2 years. Patients will be followed at 3 months and 6 months after the surgery to make sure the postoperative period is uneventful.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 1999
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 1999
CompletedFirst Submitted
Initial submission to the registry
November 3, 1999
CompletedFirst Posted
Study publicly available on registry
November 4, 1999
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2005
CompletedMarch 4, 2008
January 1, 2005
November 3, 1999
March 3, 2008
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Patients must be diagnosed with biopsy-proven glioblastoma multiforme or anaplastic astrocytoma (WHO grade III and IV, WHO classification of glial tumors) and meet the following criteria:
- Consenting males and females between the ages of 18 and 75, inclusive.
- Provided written informed consent prior to participation in the trial.
- Karnofsky Performance Scale Score greater than or equal to 60.
- Patients of all races and sexes are eligible for this study. Children and adolescents only rarely are afflicted with gliomas that are amenable for surgical resection, and so are excluded from this study.
- Patients who have been accepted for glioma resection under existing NINDS protocols are also eligible for this study.
- If tumor tissue is available from biopsy prior to surgery, we will attempt to identify tumor-specific mutation(s) prior to enrolling the patient.
You may not qualify if:
- Clinically unstable condition.
- Liver function impairment (total bilirubin greater than 2.0 mg/dl; AST or ALT greater than 3 times the upper limit of normal).
- Coagulopathy (prothrombin time \[PT\] or activated partial thromboplastin time \[APTT\] \> 1.5 times control).
- Thrombocytopenia (platelet count less than 100,000/mm3).
- Granulocytopenia (absolute neutrophil count less than 1,000/mm3).
- Acute infection.
- Acute medical problems.
- Positive HIV test.
- Karnofsky Performance Scale Score less than 60.
- Allergy to CT contrast agents.
- Absence of tumor-specific gene mutation.
- Pregnant women. Women of child-bearing potential will undergo a urine and/or serum pregnancy test. Women who are pregnant will not be allowed to participate in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892, United States
Related Publications (3)
Bernstein JJ, Woodard CA. Glioblastoma cells do not intravasate into blood vessels. Neurosurgery. 1995 Jan;36(1):124-32; discussion 132. doi: 10.1227/00006123-199501000-00016.
PMID: 7708148BACKGROUNDBrew BJ, Garrick R. Gliomas presenting outside the central nervous system. Clin Exp Neurol. 1987;23:111-7.
PMID: 2822301BACKGROUNDChretien F, Gray F, Funalot B, Authier FJ, Peltier E, Lange F, Degos JD, Poirier J. [Extracerebral metastases of a glioblastoma, in the absence of surgery]. Arch Anat Cytol Pathol. 1995;43(5-6):342-9. French.
PMID: 8729851BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Sponsor Type
- NIH
Study Record Dates
First Submitted
November 3, 1999
First Posted
November 4, 1999
Study Start
October 1, 1999
Study Completion
January 1, 2005
Last Updated
March 4, 2008
Record last verified: 2005-01